Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 6 May 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|1||Details of the person discharging managerial responsibilities/person closely associated|
|a)||Name of the Board member/Executive/Associated Person||Sylvie Grégoire |
|2||Reason for the notification|
|a)||Position/status||Member of the Board of Directors |
Closely associated person to the member.
|b)||Initial notification/Amendment||Initial notification|
|3||Details of the issuer|
|a)||Name||Novo Nordisk A/S|
|4||Details of the transaction(s)|
|a)||Description of the financial instrument,|
type of instrument,
|b)||Nature of the transaction||Purchase of ADRs|
|c)||Price(s) and volume(s)|
|DKK 789.74||1,000 ADRs|
|d)||Aggregated information |
|e)||Date of the transaction||2022-05-04|
|f)||Place of the transaction||Outside Trading Venue|
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
|Ambre Brown Morley||+45 3079 email@example.com|
|Natalia Salomao Abrahao (US)||+1 848 304 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|David Heiberg Landsted||+45 3077 email@example.com|
|Jacob Martin Wiborg Rode||+45 3075 firstname.lastname@example.org|
|Mark Joseph Root (US)||+1 848 213 email@example.com|
Company announcement No 41 / 2022
Upcoming Life Sciences Events
- May 2022
- Pharma-Biotech Product & Company Valuation with Dr. P Frei
- June 2022
- Digital RESI
- Product & Company Valuation Course
Latest company news
There are currently no news available for this portal